[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2006000175A - Heterociclos de 1,4-dihidropiridina condensados, procesos para preparar los mismos, uso y composiciones que los contienen - Google Patents

Heterociclos de 1,4-dihidropiridina condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Info

Publication number
DOP2006000175A
DOP2006000175A DO2006000175A DO2006000175A DOP2006000175A DO P2006000175 A DOP2006000175 A DO P2006000175A DO 2006000175 A DO2006000175 A DO 2006000175A DO 2006000175 A DO2006000175 A DO 2006000175A DO P2006000175 A DOP2006000175 A DO P2006000175A
Authority
DO
Dominican Republic
Prior art keywords
prepare
processes
condensed
compositions containing
dihydropiridine
Prior art date
Application number
DO2006000175A
Other languages
English (en)
Inventor
Anil Nair
Kirsten Bjergarde
Jacques Mauger
Nina Ma
Bruno Filoche-Romme
Odile Angouillant-Boniface
Serge Mignani
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of DOP2006000175A publication Critical patent/DOP2006000175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, use y composiciones que los contienen. La invencion se refiere a heterociclos dihidropiridina-condensados sustituidos utiles para el tratamiento de enfermedad de cancer, especialmente para prevenir la division de celulas cancerigenas. Estos compuestos actuan como inhibidores de Aurora A y/o B quinasas.
DO2006000175A 2005-07-20 2006-07-20 Heterociclos de 1,4-dihidropiridina condensados, procesos para preparar los mismos, uso y composiciones que los contienen DOP2006000175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (en) 2005-07-20 2005-07-20 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Publications (1)

Publication Number Publication Date
DOP2006000175A true DOP2006000175A (es) 2007-03-31

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000175A DOP2006000175A (es) 2005-07-20 2006-07-20 Heterociclos de 1,4-dihidropiridina condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Country Status (37)

Country Link
US (1) US8163768B2 (es)
EP (2) EP1746097B1 (es)
JP (2) JP2009501778A (es)
KR (1) KR101286796B1 (es)
CN (1) CN101243087B (es)
AR (1) AR054845A1 (es)
AT (2) ATE455115T1 (es)
AU (1) AU2006273692B8 (es)
BR (1) BRPI0614002A2 (es)
CA (1) CA2615700C (es)
CR (1) CR9663A (es)
CY (1) CY1109964T1 (es)
DE (1) DE602005018911D1 (es)
DK (1) DK1746097T3 (es)
DO (1) DOP2006000175A (es)
EA (1) EA016815B1 (es)
EC (1) ECSP078062A (es)
ES (1) ES2339676T3 (es)
HN (1) HN2008000088A (es)
HR (1) HRP20100195T1 (es)
IL (1) IL188861A0 (es)
MA (1) MA29634B1 (es)
MX (1) MX2008000902A (es)
MY (1) MY148617A (es)
NO (1) NO20080831L (es)
NZ (1) NZ592766A (es)
PE (2) PE20070212A1 (es)
PL (1) PL1746097T3 (es)
PT (1) PT1746097E (es)
RS (1) RS51351B (es)
SI (1) SI1746097T1 (es)
TN (1) TNSN08020A1 (es)
TW (1) TWI386411B (es)
UA (1) UA98928C2 (es)
UY (1) UY29685A1 (es)
WO (1) WO2007012972A2 (es)
ZA (1) ZA200800542B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
MX2014013373A (es) 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
AU2013261130A1 (en) 2012-05-15 2014-10-23 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
ME03095B (me) 2012-05-15 2019-01-20 Novartis Ag Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
LT2909204T (lt) * 2012-10-12 2019-05-10 The Broad Institute, Inc. Gsk3 inhibitoriai ir jų panaudojimo būdai
AU2015360416A1 (en) 2014-12-10 2017-06-08 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
US11180492B2 (en) 2016-01-15 2021-11-23 University Of Central Florida Research Foundation, Inc. Anti-parasitic compounds and uses thereof
WO2017143059A1 (en) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Max binders as myc modulators and uses thereof
EP3606528B1 (en) 2017-04-05 2023-10-18 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837282T2 (de) * 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
CA2391291A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
DE60103615T2 (de) 2000-03-03 2005-06-09 Abbott Laboratories, Abbott Park Tricyclische dihydropyrazolone und tricyclische dihydroisoaxazolone als kaliumkanalöffner
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
FR2823854A1 (fr) 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005016245A2 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Also Published As

Publication number Publication date
ZA200800542B (en) 2010-02-24
KR20080026658A (ko) 2008-03-25
HRP20100195T1 (hr) 2010-05-31
ES2339676T3 (es) 2010-05-24
EA016815B1 (ru) 2012-07-30
CA2615700A1 (en) 2007-02-01
WO2007012972A3 (en) 2007-04-05
DE602005018911D1 (de) 2010-03-04
EP1910366A2 (en) 2008-04-16
EP1746097B1 (en) 2010-01-13
CA2615700C (en) 2013-06-18
JP2013063987A (ja) 2013-04-11
MY148617A (en) 2013-05-15
EP1910366B1 (en) 2011-08-24
PL1746097T3 (pl) 2010-06-30
AU2006273692A1 (en) 2007-02-01
MA29634B1 (fr) 2008-07-01
TNSN08020A1 (en) 2009-07-14
RS51351B (en) 2011-02-28
AU2006273692A8 (en) 2012-12-13
CN101243087B (zh) 2013-07-24
DK1746097T3 (da) 2010-05-25
US8163768B2 (en) 2012-04-24
CN101243087A (zh) 2008-08-13
ATE455115T1 (de) 2010-01-15
SI1746097T1 (sl) 2010-05-31
AU2006273692B8 (en) 2012-12-13
NZ592766A (en) 2012-12-21
KR101286796B1 (ko) 2013-07-17
EA200800374A1 (ru) 2008-08-29
ECSP078062A (es) 2008-01-23
CY1109964T1 (el) 2014-09-10
HN2008000088A (es) 2011-05-31
CR9663A (es) 2008-02-21
ATE521611T1 (de) 2011-09-15
IL188861A0 (en) 2008-04-13
NO20080831L (no) 2008-04-03
BRPI0614002A2 (pt) 2011-03-01
PE20100718A1 (es) 2010-10-20
PE20070212A1 (es) 2007-03-21
JP2009501778A (ja) 2009-01-22
MX2008000902A (es) 2008-03-26
UY29685A1 (es) 2007-02-28
PT1746097E (pt) 2010-04-15
US20080261969A1 (en) 2008-10-23
WO2007012972A2 (en) 2007-02-01
AR054845A1 (es) 2007-07-18
TW200740812A (en) 2007-11-01
TWI386411B (zh) 2013-02-21
EP1746097A1 (en) 2007-01-24
UA98928C2 (ru) 2012-07-10
AU2006273692B2 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
DOP2006000175A (es) Heterociclos de 1,4-dihidropiridina condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
GT200900027A (es) Compuestos organicos
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20081636L (no) FAP - inhibitorer
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
UY29530A1 (es) Compuestos quimicos
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
ATE479687T1 (de) Kinaseinhibitoren
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos